Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Viridian Therapeutics ( (VRDN) ) has provided an announcement.
Viridian Therapeutics announced positive topline results from the phase 3 THRIVE-2 trial of veligrotug, a monoclonal antibody targeting IGF-1R for chronic TED. The trial met all endpoints, showing significant improvements in proptosis, diplopia, and clinical activity scores, with a favorable safety profile. This positions veligrotug as a potential market-leading therapeutic, with submission for approval expected in the second half of 2025, potentially transforming treatment standards for TED.
More about Viridian Therapeutics
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. Its primary market focus is on therapies for chronic thyroid eye disease (TED), an autoimmune condition characterized by inflammation and tissue damage around the eyes.
YTD Price Performance: -18.04%
Average Trading Volume: 1,100,087
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.41B
For an in-depth examination of VRDN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Tesla Stock Upgraded to Buy by Mizuho with a New Street-High Price Target
- 3 Penny Stocks to Watch Now, 12/17/24
- TikTok Urges U.S. Supreme Court to Halt the Ban While Meta and Google Relish
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
